SCHEMBL7199039

SCHEMBL7199039

CCOC(=O)CC1=COc2ccc(OC(C)=O)cc2O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 4/20 0.39
CA2 P00918 2/20 0.37
CA5A P35218 2/20 0.37
STK17B O94768 1/20 0.37
MEN1 O00255 2/20 0.37
USP2 O75604 2/20 0.37
RECQL P46063 1/20 0.37
FLT3 P36888 1/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
LMNA P02545 3/20 0.36
ACHE P22303 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7204042 0.89 TSHR (0.43) ALDH1A1KDM4EHPGDKMT2ACA2
SCHEMBL7205599 0.83 EGFR (0.43) ALDH1A1KDM4EHPGDNPSR1KMT2A
SCHEMBL9257011 0.81 KDM4E (0.47) ALDH1A1KDM4EHPGDNPSR1KMT2A
SCHEMBL8579581 0.76 KDM4E (0.48) ALDH1A1KDM4EHPGDNPSR1KMT2A
SCHEMBL8113907 0.72 AKR1C2 (0.47) ALDH1A1KDM4EHPGDLMNAMAPT
SCHEMBL9412091 0.72 KDM4E (0.46) ALDH1A1KDM4EKMT2ACA2CA5A
SCHEMBL2416902 0.70 LIPE (0.54) ALDH1A1HPGDNPSR1KMT2AMEN1
SCHEMBL7818300 0.67 KDM4E (0.47) ALDH1A1KDM4EKMT2ACA2CA5A
SCHEMBL8084843 0.65 KMT2A (0.54) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL28677234 0.65 KDM4E (0.49) ALDH1A1KDM4EHPGDNPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 ALDH1A1 486/4885KDM4E 2431/4885HPGD 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.